FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313644821> ?p ?o ?g. }

• W4313644821 abstract "Background The impact of biologic therapies on body mass index (BMI) in patients with inflammatory bowel disease (IBD) is unclear. This study investigates any associations between BMI, type of IBD, and the type of medications taken among patients with IBD with varying weight categories. Methods A cross sectional study was performed in an IBD tertiary care center. Data was obtained from patients with IBD attending outpatient clinics from January 1st, 2021 until November 1st, 2021. Adult patients, older than 18 years, with a diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) were recruited. The primary outcome was the association between BMI and medication used in IBD. The secondary outcome was the association between BMI and disease type and location in patients with IBD. Results The study included a total of 528 patients of which, 66.5% have CD. Patients with normal weight comprises 55.9% of the participants, while those who are underweight, overweight or obese are 3.4, 28.2, and 12.5%, respectively. None of the underweight patients had UC. Among the normal weight, overweight and obese BMI categories, 34.6% vs. 36.2% vs. 31.8% had UC, respectively. Patients who are on tumor necrosis factor inhibitors (anti-TNF) with an immunomodulator (anti-TNF combination), are more likely to be overweight or obese than patients who are not on anti-TNF combination (OR 2.86, 95% CI 1.739–4.711, p &lt; 0.001). Patients on vedolizumab are twice as likely to be overweight or obese than patients not on vedolizumab (OR 2.23, 95% CI 1.086–4.584, p &lt; 0.05). Patients with ileocolonic CD are more likely to be overweight or obese compared to other subtypes of CD (OR 1.78, 95% CI 1.14–2.77, p = 0.01). Conclusion Many patients with IBD are either obese or overweight. Patients with IBD who are on anti-TNF combination therapy or vedolizumab monotherapy are more likely to be obese and overweight. In addition, patients will ileocolonic CD are more likely to be obese or overweight." @default.
• W4313644821 created "2023-01-07" @default.
• W4313644821 creator A5008994314 @default.
• W4313644821 creator A5012847210 @default.
• W4313644821 creator A5016445054 @default.
• W4313644821 creator A5022645608 @default.
• W4313644821 creator A5025204523 @default.
• W4313644821 creator A5028189560 @default.
• W4313644821 creator A5050404504 @default.
• W4313644821 creator A5058847040 @default.
• W4313644821 creator A5080656625 @default.
• W4313644821 creator A5087576796 @default.
• W4313644821 date "2023-01-06" @default.
• W4313644821 modified "2023-10-14" @default.
• W4313644821 title "Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study" @default.
• W4313644821 cites W1054573222 @default.
• W4313644821 cites W2008785889 @default.
• W4313644821 cites W2034410633 @default.
• W4313644821 cites W2053657586 @default.
• W4313644821 cites W2056510390 @default.
• W4313644821 cites W2065043588 @default.
• W4313644821 cites W2079584533 @default.
• W4313644821 cites W2102013054 @default.
• W4313644821 cites W2127661942 @default.
• W4313644821 cites W2129649014 @default.
• W4313644821 cites W2313391595 @default.
• W4313644821 cites W2467844715 @default.
• W4313644821 cites W2519824125 @default.
• W4313644821 cites W2559678284 @default.
• W4313644821 cites W2599076725 @default.
• W4313644821 cites W2773289068 @default.
• W4313644821 cites W2804607344 @default.
• W4313644821 cites W2888701558 @default.
• W4313644821 cites W2965228282 @default.
• W4313644821 cites W2983457235 @default.
• W4313644821 cites W2985969672 @default.
• W4313644821 cites W3016987470 @default.
• W4313644821 cites W3031302918 @default.
• W4313644821 cites W3039831665 @default.
• W4313644821 cites W3090854059 @default.
• W4313644821 cites W3107527661 @default.
• W4313644821 cites W3118482118 @default.
• W4313644821 cites W3140193707 @default.
• W4313644821 cites W3177899498 @default.
• W4313644821 cites W4213441670 @default.
• W4313644821 cites W4294116629 @default.
• W4313644821 doi "https://doi.org/10.3389/fmed.2022.1045661" @default.
• W4313644821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36687448" @default.
• W4313644821 hasPublicationYear "2023" @default.
• W4313644821 type Work @default.
• W4313644821 citedByCount "0" @default.
• W4313644821 crossrefType "journal-article" @default.
• W4313644821 hasAuthorship W4313644821A5008994314 @default.
• W4313644821 hasAuthorship W4313644821A5012847210 @default.
• W4313644821 hasAuthorship W4313644821A5016445054 @default.
• W4313644821 hasAuthorship W4313644821A5022645608 @default.
• W4313644821 hasAuthorship W4313644821A5025204523 @default.
• W4313644821 hasAuthorship W4313644821A5028189560 @default.
• W4313644821 hasAuthorship W4313644821A5050404504 @default.
• W4313644821 hasAuthorship W4313644821A5058847040 @default.
• W4313644821 hasAuthorship W4313644821A5080656625 @default.
• W4313644821 hasAuthorship W4313644821A5087576796 @default.
• W4313644821 hasBestOaLocation W43136448211 @default.
• W4313644821 hasConcept C126322002 @default.
• W4313644821 hasConcept C142052008 @default.
• W4313644821 hasConcept C142724271 @default.
• W4313644821 hasConcept C17991360 @default.
• W4313644821 hasConcept C2776207728 @default.
• W4313644821 hasConcept C2777138892 @default.
• W4313644821 hasConcept C2778260677 @default.
• W4313644821 hasConcept C2779134260 @default.
• W4313644821 hasConcept C2779280984 @default.
• W4313644821 hasConcept C2780221984 @default.
• W4313644821 hasConcept C2780479503 @default.
• W4313644821 hasConcept C2780586474 @default.
• W4313644821 hasConcept C2781121325 @default.
• W4313644821 hasConcept C3020110884 @default.
• W4313644821 hasConcept C71924100 @default.
• W4313644821 hasConcept C90924648 @default.
• W4313644821 hasConceptScore W4313644821C126322002 @default.
• W4313644821 hasConceptScore W4313644821C142052008 @default.
• W4313644821 hasConceptScore W4313644821C142724271 @default.
• W4313644821 hasConceptScore W4313644821C17991360 @default.
• W4313644821 hasConceptScore W4313644821C2776207728 @default.
• W4313644821 hasConceptScore W4313644821C2777138892 @default.
• W4313644821 hasConceptScore W4313644821C2778260677 @default.
• W4313644821 hasConceptScore W4313644821C2779134260 @default.
• W4313644821 hasConceptScore W4313644821C2779280984 @default.
• W4313644821 hasConceptScore W4313644821C2780221984 @default.
• W4313644821 hasConceptScore W4313644821C2780479503 @default.
• W4313644821 hasConceptScore W4313644821C2780586474 @default.
• W4313644821 hasConceptScore W4313644821C2781121325 @default.
• W4313644821 hasConceptScore W4313644821C3020110884 @default.
• W4313644821 hasConceptScore W4313644821C71924100 @default.
• W4313644821 hasConceptScore W4313644821C90924648 @default.
• W4313644821 hasLocation W43136448211 @default.
• W4313644821 hasLocation W43136448212 @default.
• W4313644821 hasLocation W43136448213 @default.
• W4313644821 hasLocation W43136448214 @default.
• W4313644821 hasOpenAccess W4313644821 @default.

• next